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Improved treatment of thrombosed hemodinlysis access sites Mth
thrombolysis and angioplasty. We treated percutaneously 135 expanded
polytetrafluoroethylene (PTFE) prosthetic grafts which had thrombosed
using thrombolysis with urokinase followed by balloon angioplasty. Func-
tional patency was re-established in 38 of 62 (61%) using single catheter
technique, and in 62 of 73 (85%) using crossed catheter technique (P <
0.01). Hemorrhagic complications were reduced from 12.9% in the single
catheter technique to 1.4% in the crossed catheter technique (P < 0.01).
Median "primary patency after treatment" of the PTFE accesses after
successful restoration of function was 98 days. Cumulative "primary
patency after treatment" from the time of successful recanalization of the
thrombosis for the PTFE grafts was 70.5% at one month, 45.8% at 6
months, and 16.2% at 12 months. Among a smaller group of 26 PTFE
patients who were treated with only interventional radiologic procedures
(repeat thrombolysis and/or angioplasty), without surgical revision, "sec-
ondary patency after treatment" from the time of thrombosis was 92.3%
at 1 month, 80.2% at 6 months, 69.4% at 12 months, and 36.5% at 24
months. We conclude that lysis/angioplasty is a valuable means of treating
thrombosed hemodialysis access sites. The crossed catheter technique
produces superior initial technical success compared with single catheter
ulfusion of the lytic agent. "Primary patency after treatment" after successful
recanalization is relatively short, but long-term patency is improved
substantially with retreatment of recurrent failure of the access with repeat
thrombolysis and/or angioplasty.
The maintenance of vascular access in patients receiving
chronic hemodialysis remains a major clinical problem. Throm-
bosis is the principal cause of failure of both arteriovenous fistulas
(AVFs) [1, 21 and polytetrafluoroethylene (PTFE) accesses [3, 4].
The traditional management of a thrombosed access has been a
surgical thrombectomy, often with a revision, or placement of a
new access at a different site. Thrombolysis with percutaneous
transluminal balloon angioplasty (PTA) of associated vascular
stenoses has been suggested as an alternative means of salvaging
thrombosed accesses [5—11]. However, the role of thrombolysis in
the management of thrombosed accesses has not been well
defined: the reported initial success rates of thrombolysis have
varied considerably, and there are few reports of the long-term
access patency rates following thrombolytic therapy and PTA.
Recently, another technique for thrombolysis, crossed-catheter
infusion of the lytic agent, has been introduced that permits a high
rate of successful, rapid thrombolysis [7, 12]. We report here a
retrospective comparison of the success rates of thrombolysis with
single catheter and current crossed catheter techniques in PTFE
accesses, and present a report of the long-term efficacy of thrombo-
lysis in PTFE accesses.
Methods
We reviewed the records of all patients who underwent throm-
bolysis for thrombosed hemodialysis access sites (PTFE grafts and
native arteriovenous fistulae) between April 1986 and June 1992
at the University Hospital in Denver and between April 1986 and
October 1989 at the Denver Veterans Administration Medical
Center. Only the results of treatment of PTFE accesses will be
considered in this study. During these periods, unless contraindi-
cated, all PTFE accesses which had thrombosed for the first time
were treated with thrombolytic therapy using urokinase (UK).
Any subsequent rethrombosis of a PTFE access either received
additional thrombolysis or underwent access revision on the basis
of the combined recommendation of the vascular surgery, ne-
phrology, and interventional radiology services. The principal
criteria for recommending repeated thrombolysis of PTFE ac-
cesses were the number of alternative sites for a new access, the
estimated likelihood of successful surgical revision of the current
access and of successful creation of a new access, and the relative
risk of the surgical and radiological procedures. During this
period 135 infusions of UK were performed on 97 accesses in 66
patients.
Twenty-six of the patients with PTFE grafts were treated with
multiple procedures. If, after the initial lysis/angioplasty, there
was clinical suspicion for a subsequent development of a vascular
stenosis, an angiogram of the graft and venous outflow was
performed. Common reasons for referral were elevated venous
pressure, difficulty puncturing the access, and recent elevation of
pre-dialysis serum urea nitrogen level. Routine screening for
stenosis, such as quantitation of recirculation, was not employed.
PTA of any significant (>50% narrowing) venous stenosis was
performed at the time of the angiography. If the access rethrom-
bosed after the initial lysis/angioplasty in this group of 26 patients,
retreatment with lysis and angioplasty was performed.
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Definition of results
Success. Thrombolysis was considered to be successful if there
was restoration of functional access patency sufficient to permit at
least one subsequent dialysis via the access, or for those not
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receiving hemodialysis, if there was clinical and radiological evidence
of the re-establishment of access patency.
Complication. All cases were reviewed for hemorrhagic compli-
cations associated with thrombolytic therapy. Hemorrhage was
considered to be significant if there was a drop in hematocrit of
4% or greater, or if the patient received any transfusion of blood
products to replace blood loss associated with the procedure.
No other clinically significant complications occurred in this
series.
Patency. Cumulative patency was calculated using Kaplan Meier
analysis. The patency interval was determined to have ended when
the access could no longer be used for dialysis or if the patient
required a surgical revision to maintain functional patency of the
access, Two different cumulative patencies were determined for
the period after successful initial fibrinolysis/PTA. "Primary pa-
tency after treatment" was the interval from initial recanalization
until rethrombosis, surgical thrombectomy or revision, or repeat
PTA—that is, the patency interval following the initial recanali-
zation without any other radiologic or surgical manipulation to
preserve patency. "Secondary patency after treatment" was the
period of functional patency from the initial thrombolysis until
surgical revision or access failure—that is, the patency period
which included repeat angioplasty and/or thrombolysis/angio-
plasty to preserve access patency. For this study, we were inter-
ested in the results which could be attained purely with interven-
tional radiologic techniques. Therefore, for either "primary
patency after treatment" or "secondary patency after treatment"
in this analysis, the patency interval was considered to have ended
(that is, the access was considered to have failed) at the time of
surgical revision, even if the same access remained patent after
surgical revision.
Other publications [7, 13] have used the terms primary patency
and secondary patency for what we here term "primary patency
after treatment" and "secondary patency after treatment." We
have enclosed these terms in quotation marks and added the
phrase "after treatment" on the advice of a vascular surgical
colleague (R. B. Rutherford) who pointed out that, in terms of
standard definitions [14], any patency interval following revascu-
larization of a thrombosed access will be secondary patency, and
that the standard terms primary and secondary patency should not
be applied to a patency interval following a revascularization
procedure to maintain patency.
Patency interval was not determined for the three individuals
not yet receiving hemodialysis.
Statistical analysis
Success rates. Results of single versus cross catheter technique
were compared using the Pearson chi-square test. A P value of
<0.05 was considered significant.
Complications. The frequencies of bleeding complications in
the single catheter versus crossed catheter groups were compared
using Fisher's exact test. A P value of <0.05 was considered
significant.
Patency rates. Cumulative patencies of the accesses were calcu-
lated using Kaplan-Meier survival plots. Differences between the
treatment groups were evaluated using the log rank test. A P value
of <0.05 was considered significant.
Technique
Single catheter technique. Puncture of the access was made as
close as possible to the arterial anastomosis using a 16 or 18 gauge
intracath. UK was infused at 100,000 U/hr until thrombus had
cleared from the access. No lacing or higher dose infusion was
used. If clearing did not occur during the day in which the infusion
was started, the patient was admitted to the intensive care unit for
overnight observation during continued UK infusion. A checkup
fistulogram was performed the next morning. UK was continued
until clot was 95% lysed, after which balloon angioplasty was
performed on any associated venous or venous outflow, intra-
graft, or arterial stenosis.
Crossed catheter technique. When a review of the results of
single catheter technique showed a relatively high failure rate
(Results), several technical changes were instituted in our ap-
proach to the clotted access. These included the use of two
crossed catheters for UK administration, the use of multiple side
hole catheters for initial lacing of UK through the thrombus, and
manual compression at the site of any extravasation which devel-
oped. We have grouped these changes under the term, "crossed
catheter technique." The specific changes instituted were as
follows:
(1) Crossed catheter insertion. Two punctures were made on
either side of the mid-portion of the graft. Catheters were inserted
in crossing fashion, and the tip of each catheter was placed at the
arterial and venous end.
(2) Lacing procedure. We used a multiple side hole catheter
(Mewissen catheter, Medi-Tech, Watertown, Massachusetts, or
Bookstein catheter, Angio-Dynamics, Glens Falls, New York,
USA) for the lacing procedure on the venous side of the access. A
single end hole catheter, either a 5 French straight dilator or a 5
French hockey stick catheter (Kumpe catheter, Cook Inc., Bloom-
ington, Indiana, USA) was used on the arterial side. A total of
250,000 units of UK were "laced" throughout the length of the
clot in the graft by withdrawing the catheter tip through the clot
while injecting small boluses (0.2 to 1 ml) of concentrated UK
(10,000 to 25,000 U/mI) into the clot. Heparin, 5000 units, was
administered either systemically or into the thrombus at initiation
of the procedure. These technical maneuvers been described by
Bookstein et al [6, 7, 12].
(3) Infusion of UK after lacing. After lacing of 250,000 units of
UK throughout the clot, the catheters were placed with the tip of
the arterially directed catheter within the graft just distal to the
arterial anastomosis. The venous directed catheter was placed in
the mid-portion of the graft. UK was infused through each cathe-
ter (two level infusion) at 50,000 to 75,000 U/hr (total 100,000 to
150,000 U/hr). UK infusion was continued until there was 95%
lysis. Balloon angioplasty was performed on any associated ve-
nous, intra-graft, or arterial stenosis.
(4) Manual compression of bleeding sites. If extravasation from a
previous puncture site developed during administration of UK,
manual compression was applied to the bleeding point. Bleeding
was usually manifest by swelling over the graft rather than
external bleeding; the bleeding point was localized under fluoros-
copy by injection of a small amount of contrast through the
catheter. If bleeding persisted after 20 to 30 minutes of compres-
sion, we dilated the outflow stenosis in the presence of residual
mural thrombus, and macerated intragraft thrombus with short-
duration expansions of the balioon, to re-establish flow.
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Table 1. Results of lysis/PTA in thrombosed PTFE grafts
Single catheter
techniqueN=62
Crossed catheter
techniqueN=73
Successful thrombolysis 38 (61%) 62 (85%)
Hemorrhage 8 (12.9%) 1(1.4%)
Patient demographics
One hundred and thirty-five infusions of UK were performed
on 97 access sites in 66 patients, of whom 37 were male and 29
female. The patients ranged in age at the time of the procedure
from 14.3 to 80.5 years, with a median age of 47.3 years.
Twenty-three of the patients had renal failure from diabetes
mellitus, 13 from hypertension, 12 from chronic glomerulonephri-
tis, 3 from renal vascular disease, 4 from obstruction, 3 from
rapidly progressive glomerulonephritis, 2 from refiux nephropa-
thy, 2 from trauma, and 1 from hereditary nephritis. The etiology
of the renal failure of three patients was unknown. All but three
of the patients had end-stage renal disease treated with chronic
hemodialysis. Three patients had had placement of access sites in
anticipation of hemodialysis but had not yet been started on
hemodialysis.
Results
Immediate success
Immediate results are summarized in Table 1. Using the single-
catheter technique there were 38 successful thrombolytic treatments
of thrombosed PTFE accesses out of 62 infusions (61%) of UK in 35
patients. Of the 24 unsuccessful thrombolyses 11(46%) were termi-
nated because of extravasation through a previous dialysis puncture
site. The remaining failures were due to incomplete thrombolysis (N
= 9) or to vascular stenoses that were refractory to angioplasty (N =
4), precluding subsequent use of recanalized access. In four of the
patients who had incomplete lysis there was obstruction of a major
vein distal to the graft which was thought to be chronic. Sixty-two of
the 73 crossed catheter infusions (85%) in 38 patients with PTFE
accesses were successful. Of the eleven failures in the crossed
catheter infusion group, only one (9.1%) was due to extravasation
from a prior puncture. This graft was four weeks old and at
subsequent surgery had complete disruption of the distal anastomo-
sis which produced complete outflow obstruction, exacerbating the
extravasation. Other causes of failure included: failure to complete
the infusion because of lack of an intensive care unit bed (N = 1) and
inadvertent catheter removal during infusion (N = 1); recurrent
thrombosis after successful lysis without an apparent anatomic cause
(N = 3); nondilatable venous stenosis after successful lysis (N = 2);
lack of cooperation in a retarded patient (N = 1). In two patients
there was successful restoration of flow but the graft was revised
surgically before the patient's next dialysis.
The thrombolysis success rate (Table 1) using crossed catheter
technique was significantly greater than with single catheter
technique (Pearson chi square test = 9.75075, P = 0.00179). In
order to eliminate possible bias created from multiple treatments,
the success rates for the first lytic treatment only were calculated.
Ninety-seven infusions were performed as first treatments of a
clotted access, of which 66 (68%) were successful. There were 27
of 49 (55%) successful first treatments with single catheter
technique, and 39 of 48 (81%) successful first treatments using
crossed catheter technique. This difference was also statistically
significant (Pearson chi square test 7.62393, P = 0.00576). In
addition there were 38 repeat treatments of urokinase, noted
below, of which 34 (89%) were successful.
Complications
Nine hemorrhagic complications of thrombolysis occurred dur-
ing the study in six patients (Table 1). Eight hemorrhages
occurred with single catheter infusion, the other with crossed
catheter technique. Because of the smaller numbers of hemor-
rhagic complications, Fisher's exact test was used to compare the
frequencies of bleeding complications for single versus crossed
catheter technique. There was a significantly lower complication
rate associated with the crossed catheter technique (P = 0.00411).
All of the patients with hemorrhagic complications received
transfusions, with a median of 1.5 r (range ito 4 g) of packed red
blood cells (prbc). There were three upper gastrointestinal hem-
orrhages in two patients, from undefined sites. The blood loss in
the other patients was due to extravasation from previous punc-
ture sites in the access.
Long-term outcome
During the follow-up period of "primary patency after treat-
ment" 46 PTFE grafts failed. At the conclusion of the study 12
grafts remained patent without further thrombolysis. One patient
died with a patent graft 92 days after thrombolysis, of causes
unrelated to the thrombolysis. Six patients were lost to follow-up,
including two who had renal transplantation with a patent access,
and one who converted to chronic peritoneal dialysis for reasons
unrelated to access function. For the purpose of analyzing cumu-
lative patency, the patients who underwent transplantation or
conversion to peritoneal dialysis were considered to be lost to
follow-up at the time of their last hemodialysis, except for the
individual whose allograft failed during the study period. In this
case the patency period was the cumulative time the PTFE graft
was used for hemodialysis prior to transplantation and after
resumption of hemodialysis.
Cumulative "primary patency after treatment" was calculated
both including and excluding initial technical failures (Fig. 1). The
latter cumulative patency (initial failures excluded) was calculated
to determine the cumulative patency after successful revascular-
ization.
Sixty-six accesses had successful lysis in a total of 97 single
catheter or crossed catheter treatments given for a first thrombo-
sis (overall success rate 68%). For follow-up, one access was
excluded because the patient was not yet undergoing chronic
hemodialysis. Cumulative "primary patency after treatment" for
the remaining 65 accesses is shown in Figure 1. Including initial
failures of 32%, their "primary patency after treatment" was
47.8% at 1 month, 31.0% at 6 months, and 11.0% at 12 months.
Median patency was 14 days (95% confidence interval, 0 to 36
days). For successfully treated accesses (excluding initial failures),
"primary patency after treatment" was 70.5% at 1 month, 45.8%
at 6 months, and 16.2% at 12 months. The median patency was 98
days (95% confidence interval, 0 to 215 days).
There were two treatment groups among the patients with
PTFE grafts. One group had only one lysis/angioplasty. The other
group had more than one treatment to maintain patency. Separate
cumulative "primary patency after treatment" was calculated for
the patients who had only one treatment, and for the patients who
had multiple treatments. For the group who had multiple treat-
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ments, a "secondary patency after treatment" was calculated as
well.
Twenty-six patients with 26 PTFE accesses which had initially
successful lysis/angioplasty underwent a more aggressive approach
to access salvage. The approach involved either repeat thrombol-
ysis and angioplasty if the access rethrombosed or a subclavian
vein thrombosed, or angioplasty alone of recurrent stenoses in
patent grafts. Twelve accesses underwent one more thrombolysis,
seven were lysed two more times, and four were lysed three more
times. Thirty-four of the 38 repeat UK treatments (89%) were
successful. Five nonthrombosed accesses underwent a single
angioplasty. There was one thrombosed subclavian vein, which
was treated with thrombolysis and angioplasty. The median
number of maintenance procedures after the initial lysistPTA was
two (range 1 to 31). One access, the last site available in this
patient, underwent three thrombolysisfPTAs and 27 PTAS over a
50 month period, after which surgical revision of the graft was
performed. After this revision, three additional PTAs and one
thrombolysis have kept the access functioning 76 months after the
initial graft thrombosis was treated with lysisfPTA. Excluding this
access, the mean number of maintenance procedures after the
initial lysislPTA was 1.9 per patient.
Figure 2 shows the "primary patency after treatment" (after the
first lysis/PTA) for these 26 patients, and the patency with
repeated treatments of the same 26 accesses ("secondary patency
after treatment"). "Primary patency after treatment" (after the
first lysis/PTA) at 1, 6, and 12 months was 80%, 38%, and 8%.
Median "primary patency after treatment" was 90 days (95%
confidence interval, 20 to 160 days). Median "secondary patency
after treatment" was 689 days (95% confidence interval, 342 to
1036 days). "Secondary patency after treatment" at 1 month was
92.3%, at 6 months 80.2%, at 12 months 69.4%, and at 24 months
36.5%.
Thirty-nine accesses in 33 patients had a single successful
treatment with no further interventional radiologic treatment.
Excluding initial failures, their "primary patency after treatment"
was 63.5% at 1 month, 52.5% at 6 months, and 30.9% at 12
months. Median patency was 195 days (95% confidence interval,
0 to 427 days). There is no statistical difference, as determined by
log rank test, between the "primary patency after treatment" of
the 39 accesses treated once versus the "primary patency after
treatment" of the 26 accesses in the multiple treatment group
(Fig. 2, lower curve). On the other hand, there is a statistically
significant difference between the "primary patency after treat-
ment" for the 39 patients treated only once versus the "secondary
patency after treatment" of the multiple treatment group (Fig. 2,
top curve; log rank statistic 6.65, P 0.0099).
Discussion
We have presented the largest follow-up of thrombolytic infu-
sions in clotted PTFE accesses yet reported, and the first study
comparing two techniques of lysis. Improvement in technical
success occurred when we instituted several changes from our
original single catheter technique—the use of crossed catheters,
lacing of the clot with UK using multiple hole catheters, manual
compression to control any bleeding from previous access punc-
ture sites. For brevity, we have lumped these changes under the
term "crossed catheter technique." While the majority of acutely
thrombosed PTFE accesses were successfully lysed by either
single catheter technique and crossed catheter technique, our
results demonstrate that crossed catheter technique had a mark-
edly higher rate of successful thrombolysis than did single catheter
technique. The effect of each individual component of crossed
catheter technique in producing the improved initial technical
success cannot be determined. This 85% success rate with crossed
catheter technique is higher than previously reported with single
catheter technique with UK or streptokinase [5, 9, 15—17] and is
similar to the 70 to 90% success rates reported with surgical
thrombectomy [1, 4, 18, 19]. Two other groups of investigators
have reported similar lysis rates with the use of the crossed
catheter technique [6, 7, 12, 20, 21]. Thrombolysis/angioplasty of
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clotted access sites is routinely performed in an outpatient setting
by ourselves and others [7, 20, 21], with hemodialysis the same
day.
The only significant complication associated with thrombolysis
was hemorrhage. The rate of hemorrhage with crossed catheter
technique was 1.4%, significantly lower than the 12.9% hemor-
rhagic rate we observed with single-catheter technique. Of the
failed treatments, hemorrhage was the cause of failure in 46% of
the single catheter group, and of only 9.1% of the cross catheter
group. Although we do not have the relative times to completion
of lysis for our patients, we believe the lower rate of hemorrhage
in PTFE accesses treated with crossed catheter technique verses
single catheter technique is a consequence of more rapid throm-
bolysis and re-establishment of graft flow by the crossed catheter
technique, combined with prompt manual compression to control
any local sites of hemorrhage. Bookstein et al [6, 7, 12] have
shown that more thorough distribution of the thrombolytic agent
throughout the thrombus, by either manual rotation of the catheter,
or the use of catheters with multiple side-ports to administer small
pulses of thrombolytic agent, produces more rapid lysis of throm-
bus. Lysis using crossed catheter technique has been performed
with a mean time of less than 50 minutes [7, 20, 21].
There was a high rate of rethrombosis after thrombolysis, with
half of the grafts reoccluding within slightly more than three
months (98 days) after the initial successful revascularization if no
further measures were taken to preserve patency (Fig. 1). Similar
rates of rethrombosis have been reported by others following
thrombolysis [7], and surgical revision [22]. The etiology of these
rapid rethromboses is not certain. Possibilities include recurrent
or chronic hypotension, recurrence of corrected stenoses by
elastic recoil or further intimal hyperplasia, or unrepaired single
or multiple other stenoses, including intragraft stenoses [13, 23].
Our long-term "primary patency after treatment" rate is similar to
the only other reported experience [7], while our "secondary
patency after treatment" is slightly higher. Other reports of
thrombolysis/PTA of clotted PTFE accesses [11, 15, 17] do not
provide sufficient long-term follow-up to estimate one year sur-
vival.
Those patients who had initially successful revascularization
with thrombolysis/angioplasty, and who were subsequently man-
aged with repeated angioplasty, repeated thrombolysis, or both,
had excellent long-term cumulative patency—69.4% cumulative
patency at 12 months and 36.5% cumulative patency at 24 months
after the initial thrombosis. The efficacy of repeated surgical
revisions is already recognized. In one series up to eight revisions
were performed to maintain patency of an access [22]. In our
multiple treatment group, prolonged access salvage was achieved
without surgical revision, thereby saving other potential access
sites. The question arises in our series whether a selection bias in
which individuals whose accesses were more likely to maintain
long-term patency with angioplasty, thrombolysis or both may
have contributed. However, the fact that there was no statistical
difference between the "primary patency after treatment" for the
patients treated only once vs. those treated multiple times (Fig. 2,
lower curve) suggests that there was no selection bias favoring the
multiple treatment group. On the other hand, there is a statisti-
cally significant difference between the "primary patency after
treatment" for the 39 patients treated only once versus the
"secondary patency after treatment" of the multiple treatment
group (Fig. 2, top curve; log rank statistic 6.65, P 0.0099). This
indicates that multiple treatments were effective in preserving
access function in the PTFE grafts beyond the initial successful
treatment. Prospective studies will be needed to define the
population likely to respond to multiple radiological salvage
procedures. Routine screening of non-thrombosed PTFE accesses
to detect venous anastomotic stenoses, not performed in our
patients, with angioplasty as indicated [13, 24—26], increases the
post-thrombolytic access survival rates.
The long-term patency rates following surgical thrombectomy/
revision of thrombosed access sites are not well defined; most
reports of the efficacy of surgical thrombectomy give patency rates
from the time of access creation rather than cumulative patency
following thrombectomy [1, 19, 22, 27—30], thus masking the
relatively short-term effect of a single revision. The report by
Puckett and Lindsay is the only one of which we are aware that
lists the patency after the first successful surgical salvage of an
access [23]. Their one year patency rates of 15 and 36% are similar
to our "primary patency after treatment" rate (16%) at one year,
and significantly less than the 69% patency we achieved with
multiple treatments. In addition, they do not indicate whether
surgical salvage was routinely performed on all patients following
the initial thrombosis. Thus, their patency rates may be for a
selected population and may not reflect the long-term efficacy of
this procedure performed on a random population of thrombosed
PTFE accesses.
Our results suggest that thrombolysis with PTA is as efficacious
as surgical thrombectomy/revision for immediate restoration of
function of thrombosed PTFE accesses, with a low complication
rate, without the need for a surgical procedure, and without the
sacrifice of potential future access sites. Surgical interposition
bypass of outflow stenoses, by extending the vascular access graft
proximally, may preclude the placement of subsequent accesses in
that portion of the extremity. In view of the relatively low
secondary patency rates for prosthetic accesses—two year survival
rates of 60% or less in many series [4, 28, 29, 31, 32]—it is crucial
to save potential sites for other accesses. For long-term efficacy,
repeated radiologic interventions as appropriate offer greater
patency than a single radiologic or surgical revision. There are
insufficient data in the literature to compare the cumulative
patencies attained from the time of initially successful revascular-
ization for repeated radiologic revisions versus repeated surgical
revisions.
Addendum
Our current protocol, which is updated at least annually, and technical
tips for dealing with problems likely to be encountered, can be obtained
from the address listed for reprint requests.
Reprint requests to David A. Kumpe, MD., Department of Radiology—
Box A030, Universiiy Hospital, 4200 East Ninth Avenue, Denver, Colorado,
80262, USA.
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